clinical info.hiv.gov

Offering Information on HIV/AIDS Treatment, Prevention, and Research

Guidance for Covid-19 and People with HIV is now available.

Clinical Guidelines

Federally approved medical practice guidelines for HIV/AIDS.

Drug Database

Information on FDA-approved HIV/AIDS and opportunistic infection drugs and investigational HIV/AIDS drugs.

Glossary

Medical dictionary of HIV-related terms.

Resources

HIV-related resources from the National Institutes of Health.

Mobile Application

The Clinical Info mobile application gives access to federally approved treatment and research information for HIV and AIDS, optimized for mobile devices free of charge.

Download the beta version of the Clinical Info App for your iOS or Android device.

Table 5. Common or Serious Adverse Reactions Associated with Systemically Administered Drugs Used to Treat Opportunistic Infections

Read more about Table 5. Common or Serious Adverse Reactions Associated with Systemically Administered Drugs Used to Treat Opportunistic Infections

Table 4. Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections

Read more about Table 4. Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections

Table 3. Indications for Discontinuing and Restarting Opportunistic Infection Prophylaxis in HIV-Infected Adults and Adolescents

Read more about Table 3. Indications for Discontinuing and Restarting Opportunistic Infection Prophylaxis in HIV-Infected Adults and Adolescents

Table 2. Treatment of AIDS-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

Read more about Table 2. Treatment of AIDS-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease

Read more about Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease

Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Read more about Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Characteristics of CD4 Post-Attachment Inhibitor

Read more about Characteristics of CD4 Post-Attachment Inhibitor

Characteristics of the CCR5 Antagonist

Read more about Characteristics of the CCR5 Antagonist

Characteristics of the Fusion Inhibitor

Read more about Characteristics of the Fusion Inhibitor

Characteristics of Integrase Inhibitors

Read more about Characteristics of Integrase Inhibitors